Effect of gender on the progression of nondiabetic renal disease: A meta-analysis

Journal of the American Society of Nephrology

Volumn 11, Issue 2, 2000, Pages 319-329

  Neugarten, Joel ^a,b   Acharya, Anjali ^a   Silbiger, Sharon R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHILD; CHRONIC KIDNEY DISEASE; DISEASE COURSE; FEMALE; GENDER; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL;

EID: 0033983569     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (110)

1. Silbiger S, Neugarten J: The impact of gender on the progression of chronic renal disease. Am J Kidney Dis 25: 515-533, 1995
2. D'Amico G: Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy and membranoproliferative glomerulonephritis: Survey of the recent literature. Am J Kidney Dis 20: 315-323, 1992
3. Hedges LV, Olkin I: Statistical Methods for Meta-Analysis, Orlando, FL, Academic Press, 1985
4. Johnson BT: DSTAT 1.10: Software for the Meta-Analytic Review of Research Literatures, Hillsdale, NJ, Lawrence Erlbaum Associates, 1993
5. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7: 177-188, 1986
6. Kasiske BL: Meta-analysis as a clinical tool in nephrology. Kidney Int 53: 819-825, 1998
7. Coggins CH, Lewis JB, Caggiula AW, Castaldo LS, Klahr S, Wang SR: Differences between women and men with chronic renal disease. Nephrol Dial Transplant 13: 1430-1437, 1998
8. Hannedouche T, Chauveau P, Kalou F, Albouze G, Lacour B: Factors affecting progression in advanced chronic renal failure. Clin Nephrol 39: 312-320, 1993
9. Jungers P, Hannedouche T, Itakura Y, Albouze G, Descamps-Latscha B, Man NK: Progression rate to end-stage renal failure in non-diabetic kidney diseases: A multivariate analysis of determinant factors. Nephrol Dial Transplant 10: 1353-1360, 1995
10. Hunt LP, Short CD, Mallick NP: Prognostic indicators in patients presenting with the nephrotic syndrome. Kidney Int 34: 382-388, 1988
11. Rosman JB, Langer K, Brandl M, Piers-Becht TPM, Van Der Hem GK, ter Wee PM, Donker AJM: Protein-restricted diets in chronic renal failure: A four-year follow-up shows limited indications. Kidney Int 36[Suppl 27]: S96-S102, 1989
12. Ruggenenti P, Gaspari F, Perna A, Remuzzi G: Cross-sectional longitudinal study of spot morning urine protein:creatinine ratio, 24-hour urine protein excretion rate, glomerular filtration rate, and end-stage renal failure in chronic renal disease in patients without diabetes. Br Med J 316: 504-509, 1998
13. Simon P, Ramee MP, Autuly V, Laruelle E, Charasse C, Cam G, Ang KS: Epidemiology of primary glomerular diseases in a French region: Variations according to period and age. Kidney Int 46: 1192-1198, 1994
14. Williams PS, Fass G, Bone JM: Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med 67: 343-354, 1988
15. Hannedouche T, Albouze G, Chauveau P, Lacour B, Jungers P: Effects of blood pressure and antihypertensive treatment on progression of advanced chronic renal failure. Am J Kidney Dis 21: 131-137, 1993
16. Gerstoft J, Balslov JT, Brahm M, Brun C, Jorgensen F, Jorgensen HE, Larsen M, Larsen S, Lorenzen I, Lober M, Thomsen AC: Prognosis in glomerulonephritis. Acta Med Scand 219: 179-187, 1986
17. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A: Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Nephrol Dial Transplant 11: 461-467, 1996
18. Mallick NP, Short CD, Hunt LP: How far since Ellis? The Manchester Study of Glomerular Disease. Nephron 46: 113-124, 1987
19. Hannedouche T, Chauveau P, Fehrat A, Albouze G, Jungers P: Effect of moderate protein restriction on the rate of progression of chronic renal disease. Kidney Int 36[Suppl 27]: S91-S95, 1989
20. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F: Prognostic factors in mesangial IgA glomerulonephritis: An extensive study with univariate and multivariate analyses. Am J Kidney Dis 18: 12-19, 1991
21. Bogenschutz O, Bohle A, Batz C, Wehrmann M, Pressler H, Kendziorra H, Gartner HV: IgA nephritis: On the importance of morphological and clinical parameters in the long-term prognosis of 239 patients. Am J Nephrol 10: 137-147, 1990
22. Chida Y, Tomura S, Takeuchi J: Renal survival rate of IgA nephropathy. Nephron 40: 189-194, 1985
23. Droz D, Kramar A, Nawar T, Noel LH: Primary IgA nephropathy: Prognostic factors. Contrib Nephrol 40: 202-207, 1984
24. Frimat L, Briancon S, Heston D, Aymard B, Renoult E, Huu TC, Kessler M, for L'Association des Nephrologues de l'Est: IgA nephropathy: Prognostic classification of end-stage renal failure. Nephrol Dial Transplant 12: 2569-2575, 1997
25. Packham DK, Yan HD, Hewitson TD, Nicholls KM, Fairley KF, Kincaid-Smith P, Becker GJ: The significance of focal and segmental hyalinosis and sclerosis (FSHS) and nephrotic range proteinuria in IgA nephropathy. Clin Nephrol 46: 225-229, 1996
26. Rekola S, Bergstrand A, Bucht H: Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance. Kidney Int 40: 1050-1054, 1991
27. Hood SA, Velosa JA, Holley KE, Donadio JV: IgA-IgG nephropathy: Predictive indices of progressive disease. Clin Nephrol 16: 55-62, 1981
28. Nicholls KM, Fairley KF, Dowling JP, Kincaid-Smith P: The clinical course of mesangial IgA associated nephropathy in adults. Q J Med 53: 227-250, 1984
29. Propper DJ, Power DA, Simpson JG, Edward N, Catto GRD: The incidence, mode of presentation, and prognosis of IgA nephropathy in Northeast Scotland. Semin Nephrol 7: 363-366, 1987
30. Velo M, Lozano L, Egido J, Gutierrez-Millet V, Hernando L: Natural history of IgA nephropathy in patients followed up for more than ten years in Spain. Semin Nephrol 7: 346-350, 1987
31. Wyatt RJ, Woodford SY, Julian BA: Association of macroscopic hematuria and gender with prognosis in IgA nephropathy [Abstract]. J Am Soc Nephrol 4: 691, 1993
32. van der Peet J, Arisz L, Brentjens JRH, Marrink J, Hoedemaeker PHJ: The clinical course of IgA nephropathy in adults. Clin Nephrol 8: 335-340, 1977
33. Boyce NW, Holdsworth SR, Thomson NM, Atkins RC: Clinicopathological associations in mesangial IgA nephropathy. Am J Nephrol 6: 246-252, 1986
34. Woo KT, Chiang GSC, Lau YK, Lim CH: IgA nephritis in Singapore: Clinical, prognostic indices, and treatment. Semin Nephrol 7: 379-381, 1987
35. Rambausek M, Rauterberg EW, Waldherr R, Demaine A, Krupp G, Ritz E: Evolution of IgA glomerulonephritis: Relation to morphology, immunogenetics, and bp. Semin Nephrol 7: 370-373, 1987
36. Kobayashi Y, Fujji K, Hiki Y, Tateno S, Kurokawa A, Kamiyana M: Steroid therapy in IgA nephropathy: A retrospective study in heavy proteinuric cases. Nephron 48: 12-17, 1988
37. Kobayashi Y, Hiki Y, Fujii K, Kurokawa A, Tateno S: Moderately proteinuric IgA nephropathy: Prognostic prediction of individual clinical courses and steroid therapy in progressive cases. Nephron 53: 250-256, 1989
38. Berg UB, Widstam-Attorps UC: Follow-up of renal function and urinary protein excretion in childhood IgA nephropathy. Pediatr Nephrol 7: 123-129, 1993
39. Wyatt RJ, Kritchevsky SB, Woodford SY, Miller PM, Roy S, Holland NH, Jackson E, Bishop NA: IgA nephropathy: Long-term prognosis for pediatric patients. J Pediatr 127: 913-919, 1995
40. Levy M, Gonzalez-Burchard G, Broyer M, Dommergues J, Foulard M, Sorez J, Habib R: Berger's disease: Natural history and outcome. Medicine 64: 157-180, 1985
41. Yoshikawa N, Ito H, Nakamura H: Prognostic indicators in childhood IgA nephropathy. Nephron 60: 60-67, 1992
42. Hogg RJ, Silva FG, Wyatt RJ, Reisch JS, Argyle JC, Savino DA: Prognostic indicators in children with IgA nephropathy: Report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 8: 15-20, 1994
43. Murphy BF, Fairley KF, Kincaid-Smith PS: Idiopathic membranous glomerulonephritis: Long-term follow-up in 139 cases. Clin Nephrol 30: 175-181, 1988
44. Syre G: IgA mesangial glomerulonephritis: Significance and pathogenesis of segmental-focal glomerular lesions. Virchows Arch A Pathol Anat Histopathol 402: 11-24, 1983
45. Nieuwhof C, Kruytzer M, Frederiks P, van Breda Vriesman PJC: Chronicity index and mesangial IgG deposition are risk factors for hypertension and renal failure in early IgA nephropathy. Am J Kidney Dis 31: 962-970, 1998
46. Hoy WE, Hughson MD, Smith SM, Megill DM: Mesangial proliferative glomerulonephritis in southwestern American Indians. Am J Kidney Dis 21: 486-496, 1993
47. Magil AB, Ballon HS: IgA nephropathy: Evolution of prognostic factors in patients with moderate disease. Nephron 47: 246-252, 1987
48. D'Amico G, Minetti L, Ponticelli C, Fellin G, Ferrario F, Di Belgioioso GB, Imbasciati E, Ragni A, Bertoli S, Fogazzi G, Duca G: Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med 59: 363-378, 1986
49. Cattran DC, Greenwood C, Ritchie S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 23: 247-254, 1994
50. Koyama A, Igarashi M, Kobayashi M, and The Research Group on Progressive Renal Diseases: Natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis 29: 526-532, 1997
51. Ibels LS, Gyory A: IgA nephropathy: Analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine 73: 79-102, 1994
52. Johnston PA, Brown JS, Braumholts DA, Davison AM: Clinicopathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy: A report from the MRC glomerulonephritis registry. Q J Med 84: 619-627, 1992
53. Katafuchi R, Oh Y, Hori K, Komota T, Yanase T, Ikeda K, Omura T, Fujimi S: An important role of glomerular segmental lesions on progression of IgA nephropathy: A multivariate analysis. Clin Nephrol 41: 191-198, 1994
54. Lee HS, Koh HI, Lee HB, Park HC: IgA nephropathy in Korea: A morphological and clinical study. Clin Nephrol 27: 131-140, 1987
55. Mustonen J, Pasternack A, Helin H, Nikkila M: Clinicopathologic correlations in a series of 143 patients with IgA glomerulonephritis. Am J Nephrol 5: 150-157, 1985
56. Radford MG, Donadio JV, Bergstralh FJ, Grande JP: Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 8: 199-207, 1996
57. Abe S, Amagasaki Y, Konishi K, Kato E, Iyori S, Sakaguchi H: Idiopathic membranous glomerulonephritis: Aspects of geographical differences. J Clin Pathol 39: 1193-1198, 1986
58. Cameron JS, Healy MJR, Adu D: The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. Q J Med 74: 133-156, 1990
59. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome: A controlled study of short-term prednisone treatment in adults with membranous nephropathy. N Engl J Med 301: 1301-1306, 1979
60. Davison AM, Cameron JS, Kerr DNS, Ogg CS, Wilkinson RW: The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin Nephrol 22: 61-67, 1984
61. Fuiano G, Stanziale P, Balletta M, Sepe V, Marinelli G, Comi N, Espositi A, Andreucci VE: Effectiveness of steroid therapy in different stages of membranous nephropathy. Nephrol Dial Transplant 4: 1022-1029, 1989
62. Honkanen E, Tornroth T, Gronhagen-Riska C, Sankila R: Long-term survival in idiopathic membranous glomerulonephritis: Can the course be clinically predicted? Clin Nephrol 41: 127-134, 1994
63. Hopper J Jr, Trew PA, Biava CG: Membranous nephropathy: Its relative benignity in women. Nephron 29: 18-24, 1981
64. Jindal K, West M, Bear R, Goldstein M: Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. Am J Kidney Dis 19: 61-67, 1992
65. MacTier R, Boulton Jones JM, Payton CD, McLay A: The natural history of membranous nephropathy in the west of Scotland. Q J Med 60: 793-802, 1986
66. Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini P, Grassi C, Limido D, Pasquali S, Volpini T, Sasdelli M, Locatelli F: Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 310: 946-950, 1984
67. Ramzy MH, Cameron JS, Turner DR, Neild GH, Ogg CS, Hicks J: The long-term outcome of idiopathic membranous nephropathy. Clin Nephrol 16: 13-19, 1981
68. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G: Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329: 85-89, 1993
69. Toth T, Takebayashi S: Factors contributing to the outcome in 100 adult patients with idiopathic membranous glomerulonephritis. Int Urol Nephrol 26: 93-106, 1994
70. Tu WH, Petitti DB, Biava CG, Tulunay O, Hopper J Jr: Membranous nephropathy: Predictors of terminal renal failure. Nephron 36: 118-124, 1984
71. Wehrmann M, Bohle A, Bogenschutz O, Eissele R, Freislederer A, Ohlschlegel C, Schumm G, Batz C, Gartner HV: Long-term prognosis of chronic idiopathic membranous glomerulonephritis. Clin Nephrol 31: 67-76, 1989
72. Durin S, Barbanel C, Landais P, Noel LH, Grunfeld JP: Evolution a long terme des glomerulonephrites extra-membraneuses idiopathiques: Etude des facteurs predictifs de l'insuffisance renale terminale chez 82 malades non traites. Nephrologie 11: 67-71, 1990
73. Donadio JV Jr, Torres VE, Velosa JA, Wagoner RD, Holley KE, Okamura M, Ilstrup DM, Chu CP: Idiopathic membranous nephropathy: The natural history of untreated patients. Kidney Int 33: 708-715, 1988
74. Bone JM, Rustom R, Williams PS: "Progressive" versus "indolent" idiopathic membranous glomerulonephritis. Q J Med 90: 699-706, 1997
75. Hunt LP: Statistical aspects of survival in membranous nephropathy. Nephrol Dial Transplant Suppl 1: 53-59, 1992
76. Cattran DC, Pei Y, Greenwood CMT, Ponticelli C, Passerini P, Honkanen E: Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 51: 901-907, 1997
77. Kibriya MG, Tishkov I, Nikolov D: Immunosuppressive therapy with cyclophosphamide and prednisolone in severe idiopathic membranous nephropathy. Nephrol Dial Transplant 9: 138-143, 1994
78. Pei Y, Cattran D, Greenwood C: Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 42: 960-966, 1992
79. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B, Sasdelli M, Locatelli F: A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320: 8-13, 1989
80. Zucchelli P, Ponticelli C, Cagnoli L, Passerini P: Long-term outcome of idiopathic membranous nephropathy with nephrotic syndrome. Nephrol Dial Transplant 2: 73-78, 1987
81. Bear JC, Parfrey PS, Morgan JM, Martin CJ, Cramer BC: Autosomal polycystic kidney disease: New information for genetic counseling. Am J Med Genet 43: 548-553, 1992
82. Choukroun G, Itakura Y, Albouze G, Christophe JL, Man NK, Grunfeld JP, Jungers P: Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 6: 1634-1642, 1995
83. Johnson AM, Gabow PA: Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 8: 1560-1567, 1997
84. Modification of Diet in Renal Disease Study Group: Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. J Am Soc Nephrol 5: 2037-2047, 1995
85. Stewart JH: End-stage renal failure appears earlier in men than in women with polycystic kidney disease. Am J Kidney Dis 24: 181-183, 1994
86. Higashihara E, Yoshio A, Shimazaki J, Ito H, Koiso K, Sakai O: Clinical aspects of polycystic kidney disease. J Urol 147: 329-332, 1992
87. Torra R, Badenas C, Darnell A, Nicolau C, Volpini V, Revert L, Estivill X: Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. J Am Soc Nephrol 7: 2142-2151, 1996
88. Geberth S, Ritz E, Zeier M, Stier E: Anticipation of age at renal death in autosomal dominant polycystic kidney disease (AD-PKD)? Nephrol Dial Transplant 10: 1603-1606, 1995
89. Gonzalo A, Gallego A, Tato A, Ortuno J: Age at renal replacement therapy in autosomal dominant polycystic kidney disease [Letter]. Nephron 74: 620, 1996
90. Gonzalo A, Gallego A, Rivera M, Orte L, Ortuno J: Influence of hypertension on early renal insufficiency in autosomal dominant polycystic kidney disease. Nephron 72: 225-230, 1996
91. Conte F, Serbelloni P, Milani S, and the Italian ADPKD Cooperative Study Group: Clinical data of a cooperative Italian study of ADPKD. Contrib Nephrol 115: 72-87, 1995
92. Simon P, Working Party on ADPKD: Prognosis of autosomal dominant polycystic kidney disease. Nephron 71: 247-248, 1995
93. Churchill DN, Bear JC, Morgan J, Payne RH, McManamon PJ, Gault MH: Prognosis of adult onset polycystic kidney disease re-evaluated. Kidney Int 26: 190-193, 1984
94. Davies F, Coles GA, Harper PS, Williams AJ, Evans C, Cochlin D: Polycystic kidney disease re-evaluated: A population based study. Q J Med 290: 477-485, 1991
95. Yium J, Gabow P, Johnson A, Kimberling W, Martinez-Maldonado M: Autosomal dominant polycystic kidney disease in blacks: Clinical course and effects of sickle-cell hemoglobin. J Am Soc Nephrol 4: 1670-1674, 1993
96. Iglesias CG, Torres VE, Offord KP, Holley KE, Beard M, Kurland LT: Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota, 1935-1980. Am J Kidney Dis 2: 630-639, 1983
97. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH: Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41: 1311-1319, 1992
98. Gretz N, Zeier M, Geberth S, Strauch M, Ritz E: Is gender a determinant for evolution of renal failure? A study in autosomal dominant polycystic kidney disease. Am J Kidney Dis 14: 178-183, 1989
99. 1 type IV collagen gene transcription is mediated by TGF-β and inhibited by estradiol. Am J Physiol 274: F252-F258, 1998
100. Kwan G, Neugarten J, Sherman M, Ding Q, Fotadar U, Lei J, Silbiger S: Effects of sex hormones on mesangial cell proliferation and collagen synthesis. Kidney Int 50: 1173-1179, 1996
101. Neugarten J, Silbiger S: Effects of sex hormones on mesangial cells. Am J Kidney Dis 26: 147-151, 1995
102. Silbiger S, Ghossein C, Neugarten J: Estradiol inhibits mesangial cell-mediated oxidation of low density lipoprotein. J Lab Clin Med 4: 385-391, 1995
103. Silbiger S, Lei J, Neugarten J: Estradiol suppresses type I collagen synthesis by mesangial cells via activation of AP-1. Kidney Int 55: 1268-1276, 1998
104. Silbiger S, Lei J, Ziyadeh FN, Neugarten J: Estradiol reverses TGF-β1-stimulated type IV collagen gene transcription in murine mesangial cells. Am J Physiol 43: F1113-F1118, 1998
105. Neugarten J, Ding Q, Friedman A, Silbiger S: Sex hormones and renal nitric oxide synthases. J Am Soc Nephrol 8: 1240-1246, 1997
106. Neugarten J, Silbiger S: The impact of gender on renal transplantation. Transplantation 58: 1145-1152, 1994
107. D'Amico G, Gentile MG, Fellin G, Manna G, Cofano F: Effect of dietary protein restriction on the progression of renal failure: A prospective randomized trial. Nephrol Dial Transplant 9: 1590-1594, 1994
108. Hogan SL, Muller KE, Jennette JC, Falk RJ: A review of the therapeutic studies in idiopathic membranous glomerulopathy. Am J Kidney Dis 25: 862-875, 1995
109. Reichert LJM, Koene RAP, Wetzels JFM: Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis 31: 1-11, 1998
110. Laluck BJ, Cattran DC: Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis 33: 1026-1032, 1999